COVID-19: Therapeutics and Their Toxicities
Identifieur interne : 000151 ( Pmc/Curation ); précédent : 000150; suivant : 000152COVID-19: Therapeutics and Their Toxicities
Auteurs : Michael A. Chary [États-Unis] ; Alexander F. Barbuto [États-Unis] ; Sudeh Izadmehr [États-Unis] ; Bryan D. Hayes [États-Unis] ; Michele M. Burns [États-Unis]Source :
- Journal of Medical Toxicology [ 1556-9039 ] ; 2020.
Abstract
SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is causing the COVID-19 pandemic. There is no current standard of care. Clinicians need to be mindful of the toxicity of a wide variety of possibly unfamiliar substances being tested or repurposed to treat COVID-19. The United States Food and Drug Administration (FDA) has provided emergency authorization for the use of chloroquine and hydroxychloroquine. These two medications may precipitate ventricular dysrhythmias, necessitating cardiac and electrolyte monitoring, and in severe cases, treatment with epinephrine and high-doses of diazepam. Recombinant protein therapeutics may cause serum sickness or immune complex deposition. Nucleic acid vaccines may introduce mutations into the human genome. ACE inhibitors and ibuprofen have been suggested to exacerbate the pathogenesis of COVID-19. Here, we review the use, mechanism of action, and toxicity of proposed COVID-19 therapeutics.
Url:
DOI: 10.1007/s13181-020-00777-5
PubMed: NONE
PubMed Central: 7192319
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000151
Links to Exploration step
PMC:7192319Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19: Therapeutics and Their Toxicities</title><author><name sortKey="Chary, Michael A" sort="Chary, Michael A" uniqKey="Chary M" first="Michael A." last="Chary">Michael A. Chary</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution>Division of Emergency Medicine, Harvard Medical Toxicology Fellowship,</institution><institution>Boston Children’s Hospital,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="GRID">grid.482852.1</institution-id><institution>Regional Center for Poison Control and Prevention Serving Massachusetts and Rhode Island,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="GRID">grid.62560.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8294</institution-id><institution>Department of Emergency Medicine,</institution><institution>Brigham and Women’s Hospital,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation></author><author><name sortKey="Barbuto, Alexander F" sort="Barbuto, Alexander F" uniqKey="Barbuto A" first="Alexander F." last="Barbuto">Alexander F. Barbuto</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution>Division of Emergency Medicine, Harvard Medical Toxicology Fellowship,</institution><institution>Boston Children’s Hospital,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="GRID">grid.482852.1</institution-id><institution>Regional Center for Poison Control and Prevention Serving Massachusetts and Rhode Island,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="GRID">grid.62560.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8294</institution-id><institution>Department of Emergency Medicine,</institution><institution>Brigham and Women’s Hospital,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation></author><author><name sortKey="Izadmehr, Sudeh" sort="Izadmehr, Sudeh" uniqKey="Izadmehr S" first="Sudeh" last="Izadmehr">Sudeh Izadmehr</name><affiliation wicri:level="2"><nlm:aff id="Aff4"><institution-wrap><institution-id institution-id-type="GRID">grid.59734.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0670 2351</institution-id><institution>Division of Hematology and Medical Oncology,</institution><institution>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai,</institution></institution-wrap>New York, NY USA</nlm:aff><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>New York</wicri:cityArea></affiliation></author><author><name sortKey="Hayes, Bryan D" sort="Hayes, Bryan D" uniqKey="Hayes B" first="Bryan D." last="Hayes">Bryan D. Hayes</name><affiliation wicri:level="2"><nlm:aff id="Aff5"><institution-wrap><institution-id institution-id-type="GRID">grid.32224.35</institution-id><institution-id institution-id-type="ISNI">0000 0004 0386 9924</institution-id><institution>Department of Pharmacy, Department of Emergency Medicine,</institution><institution>Massachusetts General Hospital,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation></author><author><name sortKey="Burns, Michele M" sort="Burns, Michele M" uniqKey="Burns M" first="Michele M." last="Burns">Michele M. Burns</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution>Division of Emergency Medicine, Harvard Medical Toxicology Fellowship,</institution><institution>Boston Children’s Hospital,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="GRID">grid.482852.1</institution-id><institution>Regional Center for Poison Control and Prevention Serving Massachusetts and Rhode Island,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmc">7192319</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192319</idno><idno type="RBID">PMC:7192319</idno><idno type="doi">10.1007/s13181-020-00777-5</idno><idno type="pmid">NONE</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000151</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000151</idno><idno type="wicri:Area/Pmc/Curation">000151</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000151</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">COVID-19: Therapeutics and Their Toxicities</title><author><name sortKey="Chary, Michael A" sort="Chary, Michael A" uniqKey="Chary M" first="Michael A." last="Chary">Michael A. Chary</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution>Division of Emergency Medicine, Harvard Medical Toxicology Fellowship,</institution><institution>Boston Children’s Hospital,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="GRID">grid.482852.1</institution-id><institution>Regional Center for Poison Control and Prevention Serving Massachusetts and Rhode Island,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="GRID">grid.62560.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8294</institution-id><institution>Department of Emergency Medicine,</institution><institution>Brigham and Women’s Hospital,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation></author><author><name sortKey="Barbuto, Alexander F" sort="Barbuto, Alexander F" uniqKey="Barbuto A" first="Alexander F." last="Barbuto">Alexander F. Barbuto</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution>Division of Emergency Medicine, Harvard Medical Toxicology Fellowship,</institution><institution>Boston Children’s Hospital,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="GRID">grid.482852.1</institution-id><institution>Regional Center for Poison Control and Prevention Serving Massachusetts and Rhode Island,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="Aff3"><institution-wrap><institution-id institution-id-type="GRID">grid.62560.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8294</institution-id><institution>Department of Emergency Medicine,</institution><institution>Brigham and Women’s Hospital,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation></author><author><name sortKey="Izadmehr, Sudeh" sort="Izadmehr, Sudeh" uniqKey="Izadmehr S" first="Sudeh" last="Izadmehr">Sudeh Izadmehr</name><affiliation wicri:level="2"><nlm:aff id="Aff4"><institution-wrap><institution-id institution-id-type="GRID">grid.59734.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0670 2351</institution-id><institution>Division of Hematology and Medical Oncology,</institution><institution>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai,</institution></institution-wrap>New York, NY USA</nlm:aff><country>États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>New York</wicri:cityArea></affiliation></author><author><name sortKey="Hayes, Bryan D" sort="Hayes, Bryan D" uniqKey="Hayes B" first="Bryan D." last="Hayes">Bryan D. Hayes</name><affiliation wicri:level="2"><nlm:aff id="Aff5"><institution-wrap><institution-id institution-id-type="GRID">grid.32224.35</institution-id><institution-id institution-id-type="ISNI">0000 0004 0386 9924</institution-id><institution>Department of Pharmacy, Department of Emergency Medicine,</institution><institution>Massachusetts General Hospital,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation></author><author><name sortKey="Burns, Michele M" sort="Burns, Michele M" uniqKey="Burns M" first="Michele M." last="Burns">Michele M. Burns</name><affiliation wicri:level="2"><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution>Division of Emergency Medicine, Harvard Medical Toxicology Fellowship,</institution><institution>Boston Children’s Hospital,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation><affiliation wicri:level="2"><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="GRID">grid.482852.1</institution-id><institution>Regional Center for Poison Control and Prevention Serving Massachusetts and Rhode Island,</institution></institution-wrap>Boston, MA USA</nlm:aff><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Boston</wicri:cityArea></affiliation></author></analytic><series><title level="j">Journal of Medical Toxicology</title><idno type="ISSN">1556-9039</idno><idno type="eISSN">1937-6995</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="Par1">SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is causing the COVID-19 pandemic. There is no current standard of care. Clinicians need to be mindful of the toxicity of a wide variety of possibly unfamiliar substances being tested or repurposed to treat COVID-19. The United States Food and Drug Administration (FDA) has provided emergency authorization for the use of chloroquine and hydroxychloroquine. These two medications may precipitate ventricular dysrhythmias, necessitating cardiac and electrolyte monitoring, and in severe cases, treatment with epinephrine and high-doses of diazepam. Recombinant protein therapeutics may cause serum sickness or immune complex deposition. Nucleic acid vaccines may introduce mutations into the human genome. ACE inhibitors and ibuprofen have been suggested to exacerbate the pathogenesis of COVID-19. Here, we review the use, mechanism of action, and toxicity of proposed COVID-19 therapeutics.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Toxicol</journal-id><journal-id journal-id-type="iso-abbrev">J Med Toxicol</journal-id><journal-title-group><journal-title>Journal of Medical Toxicology</journal-title></journal-title-group><issn pub-type="ppub">1556-9039</issn><issn pub-type="epub">1937-6995</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">7192319</article-id><article-id pub-id-type="publisher-id">777</article-id><article-id pub-id-type="doi">10.1007/s13181-020-00777-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>COVID-19: Therapeutics and Their Toxicities</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Chary</surname><given-names>Michael A.</given-names></name><address><email>michael.chary@childrens.harvard.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Barbuto</surname><given-names>Alexander F.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Izadmehr</surname><given-names>Sudeh</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hayes</surname><given-names>Bryan D.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Burns</surname><given-names>Michele M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution>Division of Emergency Medicine, Harvard Medical Toxicology Fellowship,</institution><institution>Boston Children’s Hospital,</institution></institution-wrap>Boston, MA USA</aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.482852.1</institution-id><institution>Regional Center for Poison Control and Prevention Serving Massachusetts and Rhode Island,</institution></institution-wrap>Boston, MA USA</aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.62560.37</institution-id><institution-id institution-id-type="ISNI">0000 0004 0378 8294</institution-id><institution>Department of Emergency Medicine,</institution><institution>Brigham and Women’s Hospital,</institution></institution-wrap>Boston, MA USA</aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.59734.3c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0670 2351</institution-id><institution>Division of Hematology and Medical Oncology,</institution><institution>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai,</institution></institution-wrap>New York, NY USA</aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.32224.35</institution-id><institution-id institution-id-type="ISNI">0000 0004 0386 9924</institution-id><institution>Department of Pharmacy, Department of Emergency Medicine,</institution><institution>Massachusetts General Hospital,</institution></institution-wrap>Boston, MA USA</aff></contrib-group><author-notes><fn fn-type="com"><p> Supervising Editor: Mark B. Mycyk, MD </p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>4</month><year>2020</year></pub-date><fpage>1</fpage><lpage>11</lpage><history><date date-type="received"><day>24</day><month>3</month><year>2020</year></date><date date-type="rev-recd"><day>9</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>9</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>© American College of Medical Toxicology 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is causing the COVID-19 pandemic. There is no current standard of care. Clinicians need to be mindful of the toxicity of a wide variety of possibly unfamiliar substances being tested or repurposed to treat COVID-19. The United States Food and Drug Administration (FDA) has provided emergency authorization for the use of chloroquine and hydroxychloroquine. These two medications may precipitate ventricular dysrhythmias, necessitating cardiac and electrolyte monitoring, and in severe cases, treatment with epinephrine and high-doses of diazepam. Recombinant protein therapeutics may cause serum sickness or immune complex deposition. Nucleic acid vaccines may introduce mutations into the human genome. ACE inhibitors and ibuprofen have been suggested to exacerbate the pathogenesis of COVID-19. Here, we review the use, mechanism of action, and toxicity of proposed COVID-19 therapeutics.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>Toxicity</kwd><kwd>Pandemic</kwd><kwd>Therapeutic</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000026</institution-id><institution>National Institute on Drug Abuse</institution></institution-wrap></funding-source><award-id>Loan Repayment Program</award-id><principal-award-recipient><name><surname>Chary</surname><given-names>Michael A.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006108</institution-id><institution>National Center for Advancing Translational Sciences</institution></institution-wrap></funding-source><award-id>Loan Repayment Program</award-id><principal-award-recipient><name><surname>Izadmehr</surname><given-names>Sudeh</given-names></name></principal-award-recipient></award-group></funding-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000151 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000151 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:7192319
|texte= COVID-19: Therapeutics and Their Toxicities
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:NONE" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |